News
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...
“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
10d
Clinical Trials Arena on MSNModerna’s mRNA flu shot outperforms current standard at Phase IIIThe trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results